Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels

Inês Crespo1,2, Hermínio Tão3, Ana Belen Nieto4, Olinda Rebelo5, Patrícia Domingues1,2, Ana Luísa Vital1,2, Maria del Carmen Patino6, Marcos Barbosa3,7, Maria Celeste Lopes1,2, Catarina Resende Oliveira1,7, Alberto Orfao4,9, Maria Dolores Tabernero4,8,9

1 Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2 Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal, 3 Neurosurgery Service, University Hospital of Coimbra, Coimbra, Portugal, 4 Centre for Cancer Research (ICI-IBMC-CSIC/USAL), Department of Medicine, University of Salamanca, Salamanca, Spain, 5 Neuropathology Laboratory, Neurology Service, University Hospital of Coimbra, Coimbra, Portugal, 6 Department of Statistics, University of Salamanca, Salamanca, Spain, 7 Faculty of Medicine, University of Coimbra, Coimbra, Portugal, 8 Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL), Soria, Spain, 9 Instituto Biomédico de Salamanca (IBSAL) – Research Unit of the University Hospital of Salamanca, Salamanca, Spain

Abstract

Background: Glioblastoma multiforme (GBM) displays multiple amplicons and homozygous deletions that involve relevant pathogenic genes and other genes whose role remains unknown.

Methodology: Single-nucleotide polymorphism (SNP)-arrays were used to determine the frequency of recurrent amplicons and homozygous deletions in GBM (n = 46), and to evaluate the impact of copy number alterations (CNA) on mRNA levels of the genes involved.

Principal Findings: Recurrent amplicons were detected for chromosomes 7 (50%), 12 (22%), 1 (11%), 4 (9%), 11 (4%), and 17 (4%), whereas homozygous deletions involved chromosomes 9p21 (52%) and 10q (22%). Most genes that displayed a high correlation between DNA CNA and mRNA levels were coded in the amplified chromosomes. For some amplicons the impact of DNA CNA on mRNA expression was restricted to a single gene (e.g., EGFR at 7p11.2), while for others it involved multiple genes (e.g., 11 and 5 genes at 12q14.1–q15 and 4q12, respectively). Despite homozygous del(9p21) and del(10q23.31) included multiple genes, association between these DNA CNA and RNA expression was restricted to the MTAP gene.

Conclusions: Overall, our results showed a high frequency of amplicons and homozygous deletions in GBM with variable impact on the expression of the genes involved, and they contributed to the identification of other potentially relevant genes.

Introduction

Current knowledge about the pathogenesis of glioblastoma multiforme (GBM) has unveiled the many genetic and molecular alterations of its tumoral genome [1,2,3,4,5,6]. Such alterations often result in deregulation of one or multiple oncogenic pathways, leading to increased cell proliferation and tumor growth [5,6,7,8,9]. Among other alterations, changes in the dosage, sequence or structure of cancer-related genes have been recurrently identified, mostly in cases that carry DNA copy number (CN) alterations of those chromosomal regions where such genes are coded [2,3]. In recent years, several studies have highlighted the relevance of recurrent gains of chromosome 7p, together with 10q and 9p21.3 losses, and other less frequent chromosomal alterations [10,11,12,13]. Such numerical chromosomal changes frequently reflect amplification/mutation of the EGFR gene (a tyrosine kinase receptor coded at 7p11.2) and loss of the PTEN (10q23.31) and CDKN2A (9p21.3) tumor suppressor genes [3,13,14,15,16]. In addition, the MDM4 (1q32.1), PDGFRA (4q12), CDK4 (12q14.1), and MDM2 (12q15) genes are also frequently amplified in GBM, whereas inactivation of the NF1 (17q11.2), TP53 (17p13.1) and IDH1/2 (2q34/15q26.1) genes through deletion and/or mutation is also commonly observed [8,17,18,19,20,21].

Current availability of large-scale whole genome and gene expression profiling (GEP)-arrays provides an invaluable tool for detailed delineation of those genes involved in recurrent CN alterations, and rapid assessment of their impact on the expression levels of the involved genes. Gain-of-function mutations and both silencing and other type of mutations, may lead to oncogene activation and loss of function of tumor suppressor genes,
respectively. Similarly, gene amplification and homozygous deletion may also contribute to the development of the tumoral phenotype. Consequently, detailed analysis of the recurrently involved genes in amplicons and homozygous deletions is a particularly attractive approach for identification of relevant targeted genes. Such analysis would be particularly informative when combined with parallel assessment of the impact of these alterations on the levels of expression of the candidate genes, in paired DNA and mRNA samples.

Previous array-based studies in which CN alterations are related to GEP have contributed to the identification of cancer associated genes relevant to GBM (e.g. MYCN, PIK3CA, CCND2, KRAS, CHD5, CXCL12, PTEN, LRRN6C, ERRFI1 and TACC3, and at the same time they have confirmed the pathogenic role of other known genes (e.g. EGFR) [8,22,23,24,25]. More recently, The Cancer Genome Atlas (TCGA) research network [8] has further reported occurrence of homozygous deletions of the NF1 and PARK2 genes, and amplification of the AKT3 gene – less frequently also of the FGFR2 and RB1 genes – in a series of 206 GBM. Other candidate genes for which different mechanisms of alteration (e.g. epigenetic silencing) have been reported in GBM, include the RBBP5 gene (a member of the RB pathway) amplified at 1q32 [23], the CXCL12 (CXCR4 ligand involved in chemotraffaction and tumor invasion) and the HRK (a member of the hexokinase family, known to regulate apoptotic pathways) genes [25]. Nevertheless, high-resolution analyses of somatic CN alterations from a large series of cancer specimens (n = 3,131) including GBM, identified 158 regions which are frequently altered across multiple cancer types, many of which could not be explained by previously known cancer-associated genes [27]. Despite all the above, currently there is limited information [8,23,24,25] about the impact of DNA CN alterations on gene mRNA expression levels in GBM.

In order to identify potentially targeted relevant genes, here we investigated the impact of CN alterations on the expression profile of those genes recurrently involved in amplicons and homozygous deletions in GBM. Our results show that most genes for which a high correlation was observed between CN alterations and gene expression levels, are coded in those chromosomal regions for which amplicons were detected, pointing out the potential role of several genes coded in chromosomes 12q14 (e.g. RAP1B, MDM2 and GRB14), 4q12 (e.g. TMEM165, FIP1L1 and EXO70), in addition to the EGFR gene, in GBM. Conversely, the MTAP gene coded in chromosome 9p21 was the only gene involved in homozygous deletions whose expression levels showed a significant correlation with the CN status.

Materials and Methods

Patients and samples

A total of 46 caucasian patients diagnosed with primary GBM in the absence of other known genetic disorders (except for a case – G23- who had a von Willebrandt disease -) who were admitted to the University Hospital of Coimbra (Coimbra, Portugal), were included in this study; 21 were males and 25 females with a mean age of 62±13 years (range: 30 to 84 years) (Table 1).

In the present study, only patients with magnetic resonance imaging (MRI), clinical evidence of disease and a histologically confirmed diagnosis of GBM based on the World Health Organization (WHO) criteria [28], were considered. Other criteria used for patient inclusion in the study were: i) availability of enough highly-infiltrative (>75%) tumor tissue for genetic studies, and; ii) informed consent to participate in the study given by the patient. The study was approved by the University Hospital of Coimbra Ethics Committee, according to the Declaration of Helsinki protocol.

In addition to a tumor tissue specimen, paired peripheral blood (PB) samples were also collected from each patient at diagnosis.

For every tumor sample, representative parts of fresh tumor tissues obtained by surgical resection were immediately (<30 min) snap-frozen in liquid nitrogen and stored at ~80°C until used for interphase fluorescence in situ hybridization (iFISH); GEP and single-nucleotide polymorphism (SNP)-array studies. Prior to these studies, a section cut from the tissue block was assessed by conventional histopathological procedures, to estimate its tumor cell contents. Specimens with ≤75% tumor cells, in the absence of significant contamination by normal brain parenchyma and tumor necrosis, were selected for further DNA and RNA extraction, as well as for iFISH studies.

Identification of CN alterations by SNP-arrays

For the investigation of CN alterations by SNP-arrays, DNA from frozen tumor tissue and their paired fresh PB samples was purified using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) according to the instructions of the manufacturer. DNA yield and purity were determined with a NanoDrop-1000 spectrophotometer (Nano-Drop Technologies Inc., Wilmington, DE, USA) and DNA integrity was evaluated by conventional electrophoretic procedures in a 1% agarose gel. Briefly, total DNA was digested with restriction enzymes and ligated to the corresponding adaptors, following conventional Affymetrix procedures (Affymetrix Inc., Santa Clara, CA, USA). A generic primer was used in triplicate to amplify adaptor-ligated DNA fragments, through a polymerase chain reaction (PCR). After hybridization with the sample DNA, the chips were washed, labeled with streptavidin-phycoerythrin and scanned using a GeneChip Scanner 3000 (Affymetrix Inc.).

Two different SNP-array chips were used for CN analysis: 1) the GeneChip Human Mapping 500K Array Set, which provides information according to NCBI/hg17 assembly about >500,000 SNPs (262,264 SNPs in the Nsp array and 238,304 SNPs in the Sty array), was applied for the study of 23 GBM, and; 2) the Genome-Wide Human SNP Array 6.0, which contains probes for 906,600 SNPs and 945,826 non-polymorphic probes featuring a total of >1.8 million probes (Affymetrix Inc.), was used in the other 23 GBM (Table 1). Data about a total of 500,568 and 906,600 DNA probes was obtained in duplicate for paired tumor and normal PB DNA samples for each array, and it was analyzed with the Console Genotyping software (version 3.0.2; Affymetrix Inc.). In addition, the dChip 2010 software (http://www.dchip.org; Dana Farber Institute, Harvard, MA, USA) was used to calculate CN values and plot them according to chromosomal localization. Only common SNP probes between the two types of SNP-arrays (n = 481,622) were used in the analysis. Cut-off values ≤1.30 and ≥2.50 (arbitrary units) observed in tumor samples versus those obtained in the paired normal PB DNA samples, were used to establish CN losses and gains, respectively. Amplification and homozygous deletions were defined based on CN cut-off values obtained for DNA tumoral tissue of >5 and <0.8 PB DNA copies (arbitrary units), respectively.

Gene Expression Profiles (GEP)

In a subgroup of 23 tumors, total RNA was isolated from freshly-frozen tumor tissue samples in two steps, using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) and the RNeasy Mini Kit (QiAGEN). The integrity and purity of the extracted RNA were determined using a microfluidic electrophoretic system (Agilent 2100 Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA) and 18S/28S band ratio of 1.3±0.20 was observed in all samples.

PLOS ONE | www.plosone.org
### Table 1. Clinical characteristics of GBM patients (n = 46) included in this study with information about the type of SNP-arrays used in each case to investigate DNA CN alterations.

| Case ID | Age | Gender | Karnofsky Index (%) | Tumor localization | Surgical removal | No. of relapses | Survival after surgery (months) | SNP-array analyzed |
|---------|-----|--------|---------------------|-------------------|-----------------|----------------|--------------------------------|-------------------|
| G6*     | 70  | Female | 80                  | Temporal          | ST              | 1              | 19                             | 500K              |
| G8*     | 67  | Female | 90                  | Deep              | ST              | 0              | 9                              | 500K              |
| G10*    | 35  | Female | 80                  | Temporal          | ST              | 0              | 15                             | 500K              |
| G12*    | 74  | Male   | 70                  | Temporal          | ST              | 0              | 1                              | 500K              |
| G13*    | 39  | Female | 90                  | Frontal           | ST              | 1              | 21                             | 500K              |
| G14*    | 69  | Female | 70                  | Frontal           | ST              | 0              | 0                              | 500K              |
| G15*    | 79  | Male   | 80                  | Parietal          | T               | 0              | 5                              | 500K              |
| G17*    | 30  | Female | 80                  | Temporal          | ST              | 3              | 67                             | 500K              |
| G23*    | 50  | Female | 80                  | Frontal           | ST              | 0              | 14                             | 500K              |
| G30*    | 71  | Female | 60                  | Temporal          | ST              | 0              | 9                              | 500K              |
| G34*    | 69  | Male   | 80                  | Temporal          | ST              | 0              | 5                              | 500K              |
| G35*    | 50  | Female | 50                  | Frontal           | ST              | 0              | 2                              | 500K              |
| G37*    | 70  | Male   | 80                  | Temporal          | T               | 1              | 32                             | 500K              |
| G39*    | 70  | Female | 70                  | Frontal           | ST              | 1              | 18                             | 500K              |
| G40*    | 45  | Female | 80                  | Frontal           | ST              | 1              | 15                             | 500K              |
| G42*    | 67  | Male   | 80                  | Temporal          | ST              | 0              | 2                              | 500K              |
| G44*    | 48  | Male   | 80                  | Frontal           | ST              | 0              | 22                             | 500K              |
| G45*    | 76  | Female | 60                  | Temporal          | ST              | 0              | 10                             | 500K              |
| G46*    | 62  | Male   | 60                  | Frontal           | ST              | 0              | 3                              | 500K              |
| G50*    | 84  | Male   | 70                  | Temporal          | ST              | 0              | 11                             | 500K              |
| G51*    | 60  | Male   | 60                  | Temporal          | ST              | 0              | 2                              | 500K              |
| G52*    | 56  | Male   | 90                  | Frontal           | ST              | 0              | 21                             | 500K              |
| G53*    | 74  | Male   | 60                  | Frontal           | T               | 0              | 29                             | 500K              |
| G55     | 54  | Female | 80                  | Frontal           | ST              | 1              | 17                             | 500K              |
| G65     | 69  | Female | 60                  | Parietal          | ST              | 0              | 1                              | 6.0               |
| G66     | 60  | Male   | 80                  | Occipital         | T               | 0              | 14                             | 6.0               |
| G67     | 68  | Female | 80                  | Parietal          | ST              | 0              | 35                             | 6.0               |
| G68     | 72  | Male   | 70                  | Insular           | T               | 0              | 26                             | 6.0               |
| G70     | 56  | Female | 80                  | Occipital         | ST              | 0              | 21                             | 6.0               |
| G71     | 66  | Female | 60                  | Parietal          | ST              | 0              | 10                             | 6.0               |
| G72     | 77  | Female | 70                  | Temporal          | ST              | 0              | 1                              | 6.0               |
| G73     | 78  | Female | 60                  | Parietal          | ST              | 0              | 4                              | 6.0               |
| G79     | 71  | Female | 60                  | Occipital         | ST              | 0              | 6                              | 6.0               |
| G80     | 43  | Male   | 80                  | Frontal           | T               | 1              | 18                             | 6.0               |
| G81     | 62  | Female | 70                  | Frontal           | ST              | 0              | 13                             | 6.0               |
| G82     | 78  | Male   | 70                  | Frontal           | ST              | 0              | 2                              | 6.0               |
| G83     | 75  | Male   | 70                  | Temporal          | ST              | 0              | 10                             | 6.0               |
| G87     | 45  | Male   | 80                  | Temporal          | ST              | 1              | 16                             | 6.0               |
| G88     | 71  | Male   | 80                  | Parietal          | ST              | 0              | 8                              | 6.0               |
| G89     | 51  | Male   | 80                  | Temporal          | ST              | 0              | 2                              | 6.0               |
| G90     | 57  | Female | 60                  | Parietal          | ST              | 0              | 5                              | 6.0               |
| G91     | 73  | Female | 60                  | Occipital         | ST              | 0              | 13                             | 6.0               |
| G92     | 54  | Female | 80                  | Parietal          | T               | 1              | 15                             | 6.0               |
| G93     | 63  | Male   | 80                  | Occipital         | T               | 0              | 29                             | 6.0               |
| G94     | 79  | Female | 80                  | Temporal          | ST              | 0              | 9                              | 6.0               |
| G97     | 53  | Male   | 80                  | Temporal          | T               | 0              | 21                             | 6.0               |

Surgical removal: ST- subtotal; T- total.

*Tumors analyzed by gene expression arrays.

*Only patient that remained alive at the moment of closing the study; all other patients had died.

doi:10.1371/journal.pone.0046088.t001
Alto, CA, USA) and GEP were analyzed with the Gene Chip Human Genome U133 Plus 2.0 Array (Affymetrix Inc.) according to the instructions of the manufacturer, through the one-cycle cDNA synthesis kit and the Poly-A RNA gene chip control kit (Affymetrix Inc.), as previously reported [29]. Datafiles containing expression values were normalized _Robust Multi-array average expression measure (RMA) _ and analyzed using the R (version 2.7.1; http://www.r-project.org/) and Bioconductor software tools [http://www.bioconductor.org].

**iFISH studies**

Confirmatory iFISH studies were performed in every case according to previously described methods [30], using a set of commercial dual-color fluorescence labelled probes obtained from Vysis, Inc. (Downers Grove, IL, USA) and Q-BIOgene (Carlsbad, CA, USA), as previously described in detail [29,30]; these probes included sequences for the TP73, ANPPT1L, EGFR, ELN, TES, p16, ABL1, PTEN, RB1, TP53, ZNF44, GLTSCR1, and BCR genes (Supplementary table S2). An Axioscope fluorescence microscope equipped with a ×100 oil objective (Zeiss, Gottingen, Germany) was used to count the number of hybridization spots per nuclei (≥200 nuclei/slide). Only those spots with a similar size, intensity and shape in non-overlapping nuclei, were counted; doublet signals were considered as single spots. Briefly, gains and losses of specific chromosomal regions were considered to occur when ≥5% and ≥10% of the nuclei showed an increased and decreased number of fluorescent signals (spots) with respect to normal diploid cells, respectively. Specimens were considered to carry amplification of the EGFR gene when >10% of the tumor cells exhibited either an EGFR:CEP7 ratio ≥2 or multiple tight clusters of hybridization signals for the EGFR gene probe. Homozygous deletion was defined as ≥5% of tumor nuclei with centromeric probe signals in the absence of signals for the locus specific probe.

**Real Time RT-PCR validation of microarray-based mRNA levels**

Microarray mRNA expression levels of four relevant genes (BCAS2, FIP1L1, EGFR, and XIST) coded in 4 different chromosomes (chromosomes 1, 4, 7 and X) were validated by an independent Quantitative Real-Time RT-PCR assay in a total of 14 GBM samples (G8, G10, G14, G17, G30,G34, G37, G40, G42, G44, G45, G46, G52 and G53). For this purpose the SuperScript III first-strand Synthesis System from Invitrogen (www.invitrogen.com) and both the LightCycler carousel-based system and the LightCycler TaqMan Master chemistry (Roche,Mannhein, Germany) were used, according to the instructions of the manufacturers.

**Statistical analyses**

The statistical significance of differences observed between groups was assessed by the Student T and the Mann-Whitney U tests, for parametric and non-parametric (continuous) variables, respectively; for qualitative variables, the χ² test was used (SPSS software, SPSS 15.0, SPSS Inc, Chicago, IL, USA). Survival curves were plotted according to the method of Kaplan and Meier, and the log-rank test was used to assess the statistical significance of differences in overall survival between groups of patients (SPSS software). P-values<0.05 were considered to be associated with statistical significance.

In order to investigate the impact of CN alterations on GEP, the relationship between DNA CN values and GEP mRNA levels was assessed for 12,445 genes investigated in common with both the SNP-arrays and the GEP arrays, using the Pearson correlation (Supplementary table S1). The correlation between real Time RT-PCR and microarray-based mRNA levels of the BCAS2, FIP1L1, EGFR, and XIST genes was assessed by the Spearman correlation.

**Results**

**Chromosomal localization of amplicons and homozygous deletions**

Overall, a higher number of amplicons than homozygous deletions was observed with both the 6.0 and 500KSNP-arrays. Recurrent amplicons were localized in chromosomes 7 (50% of the cases), 12 (22%), 1 (11%), 4 (9%), 11 (4%), and 17 (4%); in turn, homozygous deletions frequently involved chromosomes 9 (52%) and 10 (22%) and less frequently, chromosomes 1, 6, 12, 13, 16 and 17 (one case each).

By far, chromosome 7p11.2 was the most frequently amplified chromosomal region (n = 21/46 patients; 46%); two additional cases showed amplicons at chromosome 7q (Figure 1 and Supplementary Table S3). In turn, a high frequency of amplicons was also noted in the long arm of chromosome 12 with recurrent involvement of the 12q14.1 (8/46 cases; 17%), 12q13.3 (6/46 patients, also showing 12q14.1 amplicons; 13%) and 12q15 (4/46 patients, three of which also showed 12q14.1 amplicons; 9%) cytobands; another four cytobands of chromosome 12 _12q13.12, 12q13.13, 12q14.3 and 12q21.1_ were affected in only one tumor each. Other recurrent amplicons involved chromosomes 4q12 (4/46 patients; 9%) and 1q22.1 (3/46 patients; 7%) (Figure 1 and Supplementary Table S3). Four additional cytobands were amplified in chromosomes 11 (11p13.1,11p15.3, 11q13.3 and 11q25), and 17 (17q23.1, 17q11.1, 17q11.2 and 17q24.1) in only two tumors each (Supplementary Table S3).

In some patients, coexistence of two or three amplicons in different chromosomes was observed. These included amplicats at chromosomes 4, 7 and 12 in one case (case G82), at chromosome 7 and chromosome 12 in four patients (cases G39, G55, G70 and G71), at chromosomes 4 and 12 in another two tumors (cases G82 and G86), at chromosomes 1 and 7 in 2 other cases (cases G65 and G63), at chromosomes 7 and 11 in one patient (G23) and at chromosomes 7 and 17 in another case (G91) (Supplementary Table S3). In other cases, amplicons were restricted to a single chromosome: chromosome1 in one patient (case G79; 2%); chromosome 4 in two tumors (G12 and G73; 4%); chromosome 12 in two cases (G46 and G51; 4%) and chromosome 7 in 11 patients (G30, G37, G40, G44, G55, G67, G68, G72, G90, G91 and G94; 24%).

Recurrent homozygous deletions were only found for chromosomes 9 (52%) and 10 (22%) (Figure 2 and Supplementary Table S4). Despite homozygous deletion of chromosome 9 showed a highly variable extension, it mainly involved chromosome 9p21.3 and less frequently, chromosome 9p21.2, 9p22.1 and 9p23 (Supplementary Table S4). Ten tumors (G10, G15, G42, G55, G63, G65, G67, G70, G72, G79 and G80) showed homozygous deletions of chromosome 10 at different regions: 10q23.31, 10q23.2, 10q21.3, 10q26.3, 10p13, 10q11.21, 10q22, 10q23.33 and 10q24.32 (Figure 2 and Supplementary Table S4); homozygous deletions involving the 10q21.3 chromosomal region occurred in only four tumors (G65, G72, G79 and G80), but they frequently involved different loci; another 5 tumors (G10, G42, G55, G67 and G70) showed homozygous losses at 10q23.2–10q23.31 but, once again, they frequently involved distinct loci. Other homozygous deletions were observed in a single tumor and they involved chromosomes 13q14.2 and 12q24 (case G97).
16q22.1–16q23.2 and 1p36 (case G72), 17p12 (case G89) and 6q21 (case G80) (Supplementary Table S4).

iFISH analysis systematically confirmed the presence of the above described amplicons and homozygously deleted chromosomal regions (Supplementary Table S2); although variable patterns of numerical changes were revealed by iFISH at the single cell level, in line with previous observations [31]; such intratumoral iFISH heterogeneity was not detected by the SNP CN profiles as exemplified in Supplementary Table S5 for chromosomes 7 and 9.

Detailed characterization of the amplified and homozygously deleted chromosomal segments

Characterization of the amplified chromosomal regions in GBM revealed variable lengths for recurrent amplicons. Overall, amplified segments in chromosome 7 ranged from 280 Mb to 5,681 Mb and those at chromosome 7p11.2 systematically included the EGRF gene (n = 21 samples; 46%) frequently in association with the LANCL2 (n = 12; 26%), FSTM2A (n = 8; 17%) and TOPPI (n = 7; 15%) genes (Figure 1 and Supplementary Table S3).

Recurrently amplified segments for chromosome 12 ranged from 44 Mb to 1,479 Mb and they included distinct segments localized at 12q including up to 41 different genes (Supplementary Table S3). Among other, these included the CYP27B1, METTL1, FAM119B, TSFM and AVIL genes at chromosome 12q14.1 in 8/46 patients (17%), and the CDK4 and AGAP2 genes in 7 GBM (15%). In addition, amplification of the 12q13.3 chromosomal region involved the GEFT and B4GALNT1 genes in 6 patients (13%) and recurrent amplification of chromosome 12q15 involved the MDM2 gene together with the SLC35E3 and CPM genes in 4 cases (9%).

For those four tumors with amplicons at chromosome 4q12 (G12, G73, G82 and G88), the PDGFRA, CHIC2, LNX1, FIP1L1, and SCFD2 genes were found to be systematically amplified, the length of the amplified chromosome 4q12 region varying between 1,022 Kb to 5,251 Kb (Figure 1).

The amplified chromosomal region at 1q32.1 (n = 3/46 tumors; 7%) showed a length of between 585 Kb and 864 Kb, and it systematically included the MDM4 gene together with another seven genes (SOX13, ETP4R2, REN, KISS1, GOLT1A, PLEKHA6 and PIK3C2B (Figure 1 and Supplementary Table S3).
Another 10 chromosomal regions from chromosomes 1, 11 and 17 were amplified in only one tumor each and they involved a variable number of genes (between 1 and 37 genes) (Supplementary Table S3).

The most frequent homozygous deletion found involved chromosome 9p21.3 from the 21,978,443 bp to the 22,119,128 bp position. This segment included the **CDKN2A** gene in 24 patients (52%), together with the **CDKN2B** and **CDKN2BAS** genes in 22 of them (48%). The **MTAP** (12 cases; 26%), **LOC554202** (8 tumors; 17%), **ELAVL2** (5 GBM; 11%), and **TUSC1** (5 cases; 11%) genes were also frequently lost. Noteworthy, in a subset of 7 of the former 24 cases, homozygous deletion of the 9p21.3 segment extended telomerically to the 21,186,931 bp position including between three (n = 4 cases) and four (n = 3) genes more (**IFNA7**, **IFNA4** and **IFNA17** without or with the **KLHL9** gene, respectively) (Figure 2 and Supplementary Table S4). By contrast, the localization of the deleted regions in chromosome 10 was highly heterogeneous extending from the 13,320,848 bp to the 134,174,753 bp positions, with an overall length of between 4 to 8,726 Mbp; among these cases, the **PTEN** gene was homozygously deleted in 3 tumors (Figure 2 and Supplementary Table S4). Another two genes **DNA2** and **SLC25A16** were lost at the 10q21.3 region in another 3 cases, and twenty genes coded at the 10q23.31 chromosomal region or near it **ATAD1, LIPK, LIPN, ANKRD22, STAMBP1, ACTA2, FAS, FASAS, CH25H, LIPA, IFIT2, IFIT3, IFIT1B, IFIT1, IFI5, SLC16A12, PANK1, FLJ37201 and KIF20B** genes_ were homozygously lost in 2 other cases (Supplementary Table S4). Of note, the **RB1** tumor suppressor gene coded at chromosome 13q14.2 was homozygous deleted together with the **RCBTB2** gene in only one tumor (G97) from our series (Supplementary Table S4).

**Copy number alterations and gene expression levels**

Out of 12,445 genes present in common in both the SNP and GEP arrays (including 259/305 amplified or homozygously deleted genes), 46 genes showed a high correlation ($R^2 > 0.70$) between DNA CN values and GEP RNA levels in paired GBM tumor-PB samples (n = 23) (Table 2). Noteworthy, all except three of these 46 genes were coded in those chromosomes carrying amplifications: 10 in chromosome 1, 10 in chromosome 4, 4 in chromosome 7, 1 in chromosome 11, 10 in chromosome 12. The **MTAP** gene was the only gene coded in a homozygously deleted chromosomal region (chromosome 9p21) for which a significant
correlation was found between CN alterations and gene expression levels (Table 2). Of note, a high correlation was observed between the microarray expression levels and quantitative RT-PCR analysis of the mRNA levels of 4 selected relevant genes (BCAS2, FIP1L1, EGFR and XIST) with Spearman correlation coefficients of 0.6, 0.8, 0.8 and 0.9, respectively.

Those genes whose expression was mostly impacted by the most frequent CN alterations were the RAP1B, TSFM, CYP27B1, METTL1, AVIL, CDK4 and FAM119B genes in chromosome 12q14, the EGFR gene in chromosome 7p11 and the TMEBI165, FIP1L1, CLOCK, SRD5A3 and SCFD2 genes in chromosome 4q. As mentioned above the MTAP gene was the only gene whose expression was highly correlated to the occurrence of homozygous deletion of chromosome 9p21.

From the prognostic point of view, none of the amplified and homozygous deletions showed a clear impact on patient survival, except for the amplification of the PDGFRα gene in chromosome 4q, which was associated with a significantly shorter overall survival (median overall survival of 2 vs 13 months for the PDGFRα amplified vs non-amplified cases; p = 0.0002) (Figure 3).

Discussion

Identification of genetic markers involved in the oncogenic mechanisms and molecular pathways driving GBM, still remains a challenge. Among other approaches, detailed characterization of amplicons and homozygous deletions provides a useful tool for the screening and identification of candidate genes, despite pathogenic mechanisms (e.g. gene mutation, epigenetic silencing through gene methylation and altered expression microRNA) exist which are not directly related to CN alterations. Several techniques have been previously used for the identification of CN alterations in GBM, including high-resolution SNP-arrays [23,32,33,34]. Through such approaches, CN gains of chromosome 7p11.2, together with del(9p21) and monosomy 10/del(10q), have been commonly observed in GBM, together with other less frequent abnormalities [10,12,35]. Although the information from such analyses is useful for the identification of both the altered chromosomal regions and the genes they contain, valuable insights into the role of relevant involved genes requires further assessment of the impact of genomic aberrations on gene expression. In this study, we integrated genomic and transcriptional data from paired DNA and RNA samples from the same tumors, in order to identify those genes involved in amplicons and homozygously deleted chromosomal regions which show a parallel change in their mRNA expression levels.

Analysis of whole-genome CN alterations by SNP-arrays confirmed the presence of previously reported recurrent genomic alterations in GBM [23,5], which were further validated here by iFISH. Overall, almost every tumor in our cohort showed CN alterations in multiple chromosomes, but their frequency and extent varied significantly among different tumors, confirming the genetic complexity of GBM [31]. Interestingly however, those regions recurrently affected by CN alterations consistent with gene amplification, were restricted to a few chromosomes (chromosomes 1q, 4q, 7p and 12q). Similarly, recurrent homozygous deletions only involved chromosomes 9p21 and 10q23. Since many genes involved in gliomagenesis often reside within amplicons and/or homozygously deleted chromosomal regions, we searched for candidate genes encoded in these regions for which a correlation existed between the DNA CN values and mRNA expression levels in the same tumor sample. Noteworthy, virtually all genes which showed a high correlation (R^2 > 0.70) between DNA CN values and mRNA levels corresponded to genes coded in those six chromosomes where amplicons were recurrently observed. Amplified genes included several genes (MDM4, PDGFRα, EGFR, CDK4, and MDM2), whose amplification has been previously associated with the pathogenesis of GBM [8,18,36,37], in addition, other candidate genes were also found to be amplified at both the DNA and RNA levels and thus, to be potentially relevant in the pathogenesis of GBM.

In detail, the EGFR oncogene whose amplification defines a subset of GBM [3,38,39], was the only gene coded in the 7p11.2 amplicon for which a significantly high correlation between DNA CN values and gene expression levels was detected; although this amplicon contained other bystander genes that may be co-amplified with EGFR (e.g. LANCL2 and GASP), due to their genomic proximity [14], amplification of all such genes showed limited impact on gene expression levels. These results support and reinforce the critical role of EGFR in the pathogenesis of a significant fraction of GBM, through activation of the RAS pathway [40,41].

Amplification of chromosome 12q13–15 was also found in a significant proportion of primary GBM, in line with previous reports [17]. In contrast to 7p11.2 amplicons, 12q13–15 amplicons typically involved multiple genes whose expression was increased at the RNA level in parallel to the greater DNA CN values. However, from all these genes listed in table 2, only AVIL, FAM119B, METTL1, CYP27B1 and TSFM were systematically amplified in tumors displaying 12q amplicons. Co-amplification of the CDK4 and MDM2 genes at the 12q13–15 amplicon is frequently observed in GBM and it has been previously suggested to confer a tumor growth advantage [42]. However, in our series this amplicon showed no impact on the mRNA gene expression levels of these two genes. By contrast, relatively little is known about the role of other co-amplified and overexpressed genes which are coded in chromosome 12q13–15, even if several of them are also amplified in other tumors, e.g. in lung cancer [43]. From these genes, special attention should be paid to the AVIL and CYP27B1 genes. AVIL encodes for advillin, a member of the gelsolin/villin family of actin regulatory proteins which is almost exclusively expressed by peripheral sensory neurons, and that has been recently identified as a new candidate driver gene in GBM [44,45]. In turn, CYP27B1 (P450 Cytochrome 25-Hydroxylase) catalyzes the conversion of calcidiol to calcitriol, the most active vitamin D metabolite, involved in cell proliferation with both anti-proliferative and cell differentiating effects [46,47,48]. Conversely, the role of FAM119B [a gene of unknown function, which has been associated to multiple sclerosis] [49], METTL1, a nuclear protein that catalyzes the formation of N7-methylguanine at position 46 (m7G46) in tRNA, inactivated in response to agonists of the PI3-kinase pathway or the classical MAP kinase cascade, and TSFM (a gene that encodes the mitochondrial translation elongation factor EFTs) in GBM, deserves further investigations.

Amplification of chromosome 4q12 has been previously described to involve the PDGFRα gene in 8–15% of GBM [21,50], as also found here. However, CN alterations at 4q12 did not show a high correlation with PDGFRα mRNA levels from the same tumor. Conversely, expression of other amplified genes coded at 4q12 in the vicinity of the PDGFRα gene (e.g. FIP1L1 and SCFD2), appeared to be significantly modulated by the 4q12 amplicon, suggesting their potential relevance in GBM. In this regard, it should be noted that the FIP1L1 protein coded by the FIP1L1 gene functions as a component of the cleavage and polyadenylation specificity factor (CPSF), which participates in processing of mRNA. Although, it has been observed that fusion of the FIP1L1 gene to the PDGFRα gene generated by interstitial
Table 2. Relationship between the CN alterations and gene expression levels for 12,445 genes analyzed in parallel with the SNP and GEP arrays, in GBM (n = 23).

| Gene Name                                               | Symbol      | Cytoband      | R²  |
|---------------------------------------------------------|-------------|---------------|-----|
| Cold shock domain containing E1, RNA-binding           | CSDE1       | 1p22          | 0.93|
| Transcription termination factor, RNA polymerase II     | TTF2        | 1p22          | 0.75|
| Breast carcinoma amplified sequence 2                   | BCA52       | 1p21-p13.3    | 0.90|
| Amylase, alpha 2B (pancreatic)                         | AMY2B       | 1p21          | 0.71|
| TryptophanylRNA synthetase 2, mitochondrial             | WARS2       | 1p13.3-p13.1  | 0.85|
| Synaptotagmin VI                                        | SYT6        | 1p13.2        | 0.78|
| Mannosidase, alpha, class 1A, member 2                  | MAN1A2      | 1p13          | 0.89|
| Adenosine monophosphate deaminase 1 (isoform M)         | AMPD1       | 1p13          | 0.83|
| Immunoglobulin superfamily, member 3                    | IGSF3       | 1p13          | 0.76|
| Zinc fingerprotein 697                                  | ZNF97       | 1p12          | 0.82|
| Signal recognition particle 72kDa                       | SRP72       | 4q11          | 0.77|
| Transmembrane protein 165                               | TMEM165     | 4q12          | 0.92|
| FIP1 like 1 (S. cerevisiae)                             | FIP1L1      | 4q12          | 0.92|
| Exocyst complex component 1                             | EXOC1       | 4q12          | 0.90|
| Clock homolog (mouse)                                   | CLOCK       | 4q12          | 0.88|
| Polymerase (RNA) II (DNA directed) polypeptide B        | POLR2B      | 4q12          | 0.87|
| Steroid 5 alpha-reductase 3                             | SRD5A3      | 4q12          | 0.77|
| DCN1, defective in cullin neddylation 1, domain containing 4 | DCUN1D4 | 4q12          | 0.75|
| Chromosome 4 open reading frame 14                      | C4orf14     | 4q12          | 0.74|
| Sec1 family domain containing 2                         | SCFD2       | 4q12          | 0.71|
| Transmembrane protein 106B                              | TMEM106B    | 7p21.3        | 0.84|
| Epidermal growth factor receptor                        | EGFR        | 7p12          | 0.85|
| Peroxisome biogenesis factor 1                          | PEX1        | 7q21.2        | 0.79|
| GATA zinc finger domain containing 1                    | GATAD1      | 7q21–q22      | 0.78|
| Methylthioadenosine phosphorylase                       | MTAP        | 9p21          | 0.73|
| Eukaryotic translation initiation factor 3, subunit M    | EIF3M       | 11p13         | 0.78|
| IMP1 inner mitochondrial membrane peptidase-like *      | IMP1L       | 11p13         | 0.75|
| Amplified in osteosarcoma                               | OS9         | 12q13         | 0.86|
| Methyltransferase like 1                                | METTL1      | 12q13         | 0.82|
| Solute carrier family 16, member 7                      | SLC16A7     | 12q13         | 0.78|
| Cytochrome P450, family 27, subfamily B, polypeptide 1  | CYP27B1     | 12q13.1–q13.3 | 0.87|
| Phosphatidylinositol-5-phosphate 4-kinase, type II, gamma | PIP4K2C    | 12q13.3       | 0.90|
| Deltex 3 homolog (Drosophila)                           | DTX3        | 12q13.3       | 0.75|
| Beta-1,4-N-acetylgalactosaminyl transferase 1            | B4GALNT1    | 12q13.3       | 0.72|
| Methyl-CpG binding domain protein 6                     | MBD6        | 12q13.3       | 0.75|
| Tstranslation elongation factor, mitochondrial           | TSFM        | 12q13–q14     | 0.87|
| Carboxy-terminal domain small phosphatase 2             | CTP5D2      | 12q13–q15     | 0.91|
| RAP1B, member of RAS oncogene family                    | RAP1B       | 12q14         | 0.97|
| Cyclin-dependent kinase 4                               | CDK4        | 12q14         | 0.81|
| Family with sequence similarity 119, member B           | FAM119B     | 12q14.1       | 0.80|
| Advlillin                                                | AVL         | 12q14.1       | 0.78|
| Glutamate receptor interacting protein 1                | GRIP1       | 12q14.3       | 0.95|
| Mdm2, transformed 3T3 cell double minute 2             | MDM2        | 12q14.3–q15   | 0.96|
| Nucleo porin 107kDa                                     | NUP107      | 12q15         | 0.85|
| Solute carrier family 35, member E3                     | SLC35E3     | 12q15         | 0.79|
| X (inactive)-specific transcript *                      | XIST        | Xq13.2        | 0.96|

Only those genes (n = 46) which showed a high degree of correlation between CN alterations and RNA levels (R² > 0.70; p-value < 0.0000005) are shown.

*The IMP1L (11p13) and the XIST (Xq13.2) genes were not amplified or deleted.

doi:10.1371/journal.pone.0046088.t002
4q12 deletion, results in a constitutively activated FIP1L1-PDGFRA fusion protein with tyrosine kinase activity in chronic eosinophilic leukemia [51] the role of the FIP1L1 gene in gliomagenesis, remains to be elucidated.

Other potentially relevant genes coded at chromosome 4q12 whose CN alterations mostly impacted on their mRNA expression levels included the TMEM165 and the CLOCK genes. TMEM165 (also named TPAR1), encodes a putative transmembrane 324 amino acid protein whose cellular functions are unknown, although intronic splice mutations of the protein have been related to congenital disorders of glycosylation [52]. Of note, TMEM165 has been found to be up-regulated in invasive GBM cells with transcriptional differences between these and the other core tumor cells, supporting a role for this gene in tumor invasion [53]. In turn, the CLOCK protein contributes to activate transcription of the Period (PER1, PER2, and PER3) and Cryptochrome (CRY1 and CRY2) proteins two proteins that are involved in the circadian system. Deregulation of the circadian clock protein has been implicated in many types of cancer, in both animal and humans [54,55,56,57]. In a recent study on gliomas including GBM, tumor cell expression of PER1 and PER2 was significantly lower than in the surrounding normal/reactive cells [58], suggesting that deregulated expression of these two genes may result in disruption of the control of the normal circadian rhythm and a stimulatory effect on survival and proliferation of glioma cells. However, the molecular mechanisms of genes controlling circadian rhythm in glioma cells have not been explored so far. Independently of the precise impact of the molecular mechanisms involved, amplification at the 4q12 chromosomal region was associated with a very short patient overall survival.

Amplification of other chromosomal regions such as chromosome 1q32 was found in a relatively limited number of cases, in line with previous findings [3,8,24],. Controversial results exist as regards the impact of 1q32 amplicon on MDM4 and CNTN2, as independent versus combined targets for amplification [20]. Our results support an independent and more relevant role for the
former gene as the target of 1q32 amplification, since a higher frequency of **MDM4** amplification in the absence of involvement of **CDKN2A/B** was observed in our patients; despite this, in our series, 7 other candidate genes were amplified together with **MDM4**. These included the **PIK3CB** gene involved in the PI3K/AKT signaling pathway, which was also amplified and overexpressed in other series of GBM [20], and the **SOX13** gene, which has been reported to be up-regulated in oligodendrogliomas [59]. Despite this, none of the amplified genes at chromosome 1q32 was associated with simultaneously increased RNA expression, further investigations being required to confirm their relevance in the pathogenesis of GBM.

Commonly deleted segments at chromosome 9p21, almost systematically involve the **CDKN2A** tumor suppressor gene, in association with both the **CDKN2B** gene, and frequently also the **MTAP** gene [60,61,62,63,64], in line with our results. **CDKN2A/B** gene products are involved in the p53 pathway through the E3 ubiquitin protein ligase complex, required for mitotic progression and specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, required for mitotic progression and cytokinesis), and **IFNA4** (IFNA4, IFNA7, and **IFNA17** genes. **MTAP** is a gene involved in the PI3K/AKT signaling pathway, which has been shown to be lost independently of **CDKN2A**, which suggests that loss of **MTAP** can indeed play a role in tumor biology. Noteworthy, **MTAP** is a gene whose mRNA levels, depending on the specifically targeted gene.

Conversely, recurrent homozygous deletions were restricted to chromosome 9p21 and to multiple variable segments of chromosome 10q, the MTAP gene being the only gene whose mRNA levels were significantly affected by such homozygous deletions.

### Supporting Information

#### Table S1

| Number of probes analyzed with the two different types of SNP-arrays (6.0 and 500K SNP-arrays) and the GEP-array (U133 Plus 2.0), grouped according to their chromosomal localization. DNA CN alterations were assessed in all GBMs. | (DOC)

#### Table S2

| Genes amplified in GBM tumors (n = 46). | (DOC)

#### Table S3

| GBM tumors (n = 46): homozygously deleted genes and their corresponding cytobands in chromosomes 1, 6, 9, 10, 12, 13, 16 and 17. | (DOC)

#### Table S5

| Copy number (CN) alterations of chromosomes 7 and 9 as assessed by SNP-arrays versus iFISH analysis. | (DOCX)

### Author Contributions

Conceived and designed the experiments: AO, MDT. Performed the experiments: IC, PD, ALV, MDT. Analyzed the data: IC, ABN, MCP, AO. Conceived and designed the experiments: AO, MDT. Performed the experiments: HT, OR, ALV, MB, CRO, AO.

### References

1. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445–1453.
2. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
3. Rao SK, Edwards J, Joshi AD, Su IM, Ahn S, et al. (2009) Unsupervised analysis of glioblastoma genomic amplifications and deletions. J Neurooncol 96: 169–179.
4. Vranova V, Nesvadba E, Skrljak P, Cejpek P, Pesakova M, et al. (2007) Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization. Oncol Rep 17: 457–463.
5. Dahlback HS, Brandal P, Meling TR, Gorunova L, Scheie D, et al. (2009) **MTAP** (its absence in Drosophila causes multiple structural defects and hypotrophy of the CNS), **KLHL9** (encodes a substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, required for mitotic progression and cytokinesis), and **IFNA4** (IFNA4, IFNA7, and **IFNA17** genes. Monosomy 10 in association or not with del(10q) is a frequent finding in GBM. Despite multiple chromosomal segments were homozygously deleted in a small fraction of our cases, they rarely involved the same chromosomal regions and none of the deleted genes encoded in these areas, including the **PTEV** gene, showed a high correlation between its DNA CN values and mRNA gene expression levels.

In summary, here we confirm the high frequency of gene amplification in GBM, which mainly involves the 7p11.2, 12q13–15, and to a lesser extent also the 4q12 and 1q32 chromosomal regions. Most interestingly, amplification of those genes coded in these chromosomal segments showed a variable impact on their mRNA levels, depending on the specifically targeted gene. Conversely, recurrent homozygous deletions were restricted to chromosome 9p21 and to multiple variable segments of chromosome 10q, the MTAP gene being the only gene whose mRNA levels were significantly affected by such homozygous deletions.
Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA (2009)
38. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, et al. (2006)
37. Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, et al. (2006) High-
36. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, et al. (2009) High-
35. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, et al. (2006) Correlation
34. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The
33. Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, et al. (2009) Comparative
32. Duncan CG, Kellea PJ, Payne CA, Lampson B, Chen WC, et al. (2010) Integrated
31. Crespo I, Vital AL, Nieto AB, Rebelo O, Tao H, et al. (2011) Detailed
30. Garbina J, Lopez LC, Lee W, Cowell JK, Turpaz Y (2008) Fluidity status and number
29. Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, et al. (2010) Intratumoral patterns of clonal evolution in gliomas. Neurogenetics 11: 227–239.
28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.
27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The
26. Vitale AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, et al. (2010) Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol 12: 991–1003.
25. Li J, Beemon KG, Beemer FA, West SG, Hrycyna CA, et al. (2003) A novel circadian clock as a control point in tumor progression. J Natl Cancer Inst 94: 1201–1214.
24. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899–905.
23. Crespo I, Vital AL, Nieto AB, Rebelo O, Tao H, et al. (2011) Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn 15: 634–647.
22. Duncan CG, Kellea PJ, Payne CA, Lampson B, Chen WC, et al. (2010) Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer 49: 599–517.
21. Beroukhim R, Merrel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The
20. Riemenschneider MJ, Knobbe CB, Reifenberger G (2003) Refined mapping of 12q13–21 in glioma. Mol Cancer Res 6: 576–584.
19. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, et al. (1996) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106: 2218–2223.
18. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 81: 717–727.
17. Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, et al. (2008) A different view on DNA amplifications indicates frequent, highly complex, and stable amplons on 12q13–21 in glioma. Mol Cancer Res 6: 576–584.
16. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 81: 717–727.
15. Filipski E, King VM, Li X, Granda TG, Mormont MC, et al. (2002) Host and application to glioma. Proc Natl Acad Sci U S A 104: 20007–20012.
14. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, et al. (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106: 2218–2223.
13. Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, et al. (2008) A different view on DNA amplifications indicates frequent, highly complex, and stable amplons on 12q13–21 in glioma. Mol Cancer Res 6: 576–584.
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.
11. Kim Y, Feng L, Gao J, Wang L, Atienza CA, et al. (2007) Identification of novel candidate target genes in amplicons of Glioblastoma multiforme. Mod Pathol 20: 3792–3798.
10. Foulquier F, Amyere M, Jacken J, Zeevaert R, Schellen E, et al. (2012) MEK1M63 Deficiency Causes a Congenital Disorder of Glycosylation. Am J Hum Genet.
9. Hoelzinger DB, Mariani L, Wei J, Woyke T, Berens TJ, et al. (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7: 7–16.
8. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, et al. (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241–1246.
7. Filipski E, King VM, Li X, Granda TG, Mormont MC, et al. (2002) Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94: 690–697.
6. Hua H, Wang Y, Wan C, Lin Y, Zhu B, et al. (2007) Inhibition of tumorigenesis by intratumoral delivery of the cancer gene mPer2 in C3H/BL6 mice. Cancer Gene Ther 14: 815–818.
5. Yeh KT, Yang MY, Liu TC, Chen JC, Chang WC, et al. (2005) Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 206: 111–120.
4. Maas RM, Reus K, Diesel B, Steudel WI, Feiden W, et al. (2001) Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxysteroid D3 (CYP27B1) in human malignant glioma. Clin Cancer Res 7: 860–875.
3. Bosch X, DeAngelo DJ, Gottlieb J, Sober EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.
2. Foulquier F, Amyere M, Jacken J, Zeevaert R, Schellen E, et al. (2012) MEK1M63 Deficiency Causes a Congenital Disorder of Glycosylation. Am J Hum Genet.
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.